59 results
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
of each product in humans. Each clinical study is conducted under the auspices of an independent Institutional Review Board (“IRB”). The IRB will consider …
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Shareholders of Regen Biopharma, Inc.:
Opinion
424B3
EX-23.1
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation in this Supplement No.1 filed Pursuant to Rule 424(b
424B3
RGBP
Regen BioPharma Inc
2 Oct 23
Prospectus supplement
1:42pm
and may exceed the assets of the Company.
WE MAY HAVE DIFFICULTY IN ATTRACTING AND RETAINING MANAGEMENT AND OUTSIDE INDEPENDENT MEMBERS TO OUR BOARD … to serve on our board of directors. We may lose potential independent board members and management candidates to other companies that have greater
8-K
EX-10.1
5yac2bfkjme319z
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
vj8cjrm8ij
15 May 23
Prospectus supplement
10:25am